Chengdu Olymvax Biopharmaceuticals Inc. A
Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b. It also provides Hib conjugate vaccine and AC conjugate vaccine; and group A and C meningococcal polysaccharide conjugate vaccine. The company was fou… Read more
Chengdu Olymvax Biopharmaceuticals Inc. A (688319) - Total Liabilities
Latest total liabilities as of September 2025: CN¥976.63 Million CNY
Based on the latest financial reports, Chengdu Olymvax Biopharmaceuticals Inc. A (688319) has total liabilities worth CN¥976.63 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Chengdu Olymvax Biopharmaceuticals Inc. A - Total Liabilities Trend (2013–2024)
This chart illustrates how Chengdu Olymvax Biopharmaceuticals Inc. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Chengdu Olymvax Biopharmaceuticals Inc. A Competitors by Total Liabilities
The table below lists competitors of Chengdu Olymvax Biopharmaceuticals Inc. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Keli Sensing Technology Ningbo Co Ltd
SHG:603662
|
China | CN¥1.36 Billion |
|
alstria office REIT-AG
XETRA:AOX
|
Germany | €2.93 Billion |
|
Shanghai Zijiang Enterprise Group Co Ltd
SHG:600210
|
China | CN¥6.45 Billion |
|
K.P.R. Mill Limited
NSE:KPRMILL
|
India | ₹7.34 Billion |
|
Mesoblast Limited
F:LWB
|
Germany | €187.24 Million |
|
Sichuan Jiuzhou Electronic Co Ltd
SHE:000801
|
China | CN¥4.05 Billion |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
China | CN¥3.52 Billion |
|
GMéxico Transportes S.A.B. de C.V
PINK:GMXTF
|
USA | $72.07 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Chengdu Olymvax Biopharmaceuticals Inc. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Chengdu Olymvax Biopharmaceuticals Inc. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Chengdu Olymvax Biopharmaceuticals Inc. A (2013–2024)
The table below shows the annual total liabilities of Chengdu Olymvax Biopharmaceuticals Inc. A from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥873.54 Million | +28.12% |
| 2023-12-31 | CN¥681.84 Million | +16.15% |
| 2022-12-31 | CN¥587.02 Million | +59.85% |
| 2021-12-31 | CN¥367.22 Million | +38.95% |
| 2020-12-31 | CN¥264.29 Million | +79.54% |
| 2019-12-31 | CN¥147.20 Million | +67.49% |
| 2018-12-31 | CN¥87.89 Million | +53.09% |
| 2017-12-31 | CN¥57.41 Million | +210.88% |
| 2016-12-31 | CN¥18.47 Million | -66.25% |
| 2015-12-31 | CN¥54.72 Million | -22.50% |
| 2014-12-31 | CN¥70.60 Million | +15.90% |
| 2013-12-31 | CN¥60.92 Million | -- |